Vanda Patents For Treating ‘Non-24’ Are Obvious Federal Circuit Panel Affirms
WASHINGTON, D.C. — A federal judge in Delaware did not err in declaring obvious four Vanda Pharmaceuticals Inc. patents relating to the use of tasimelteon to treat the sleep-wake disorder known...To view the full article, register now.
Already a subscriber? Click here to view full article